{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:49:44Z","timestamp":1790704184198,"version":"4.1.0"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpm-2020-0339_abs_001_w2aab3b7c38b1b6b1aab1c16b1Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The severe acute respiratory syndrome coronavirus 2 (COVID-19) outbreak in Italy, especially in Lombardy and Bergamo city, represented probably nowadays one of the first major clusters of COVID-19 in the world. The aim of this report is to describe the activity of Bergamo Teratology Information Service (TIS) in supporting the public and health-care personnel in case of drug prescriptions in suspected\/confirmed COVID-19 pregnant and lactating patients during COVID-19 outbreak in Italy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2020-0339_abs_002_w2aab3b7c38b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All Bergamo TIS requests concerning COVID-19 pregnant and lactating women have been retrospectively evaluated from 1 March to 15 April 2020. Type of medications, drug\u2019s safety profile and compatibility with pregnancy and lactation are reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2020-0339_abs_003_w2aab3b7c38b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our service received information calls concerning 48 (9 pregnant, 35 lactating) patients. Among pregnant and lactating women, the requests of information were related to 16 and 60 drugs prescriptions respectively. More than half concerned drugs prescriptions during the first and second trimester (13\/16) and during the first six months of lactation (37\/60). Hydroxychloroquine and azithromycin were the most involved.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2020-0339_abs_004_w2aab3b7c38b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Hydroxychloroquine and azithromycin at dosages used for COVID-19 may be considered compatible and reasonably safe either in pregnancy and lactation. Antivirals may be considered acceptable in pregnancy. During lactation lopinavir and ritonavir probably exhibit some supportive data from literature that darunavir and cobicistat do not. Tocilizumab may be considered for COVID-19 treatment because no increased malformation rate were observed until now. However caution may be advised because human data are limited and the potential risk of embryo-fetal toxicity cannot be excluded.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpm-2020-0339","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T15:46:32Z","timestamp":1603208792000},"page":"1001-1007","source":"Crossref","is-referenced-by-count":7,"title":["Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy"],"prefix":"10.1515","volume":"48","author":[{"given":"Andrea","family":"Giampreti","sequence":"first","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Eleftheriou","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariapina","family":"Gallo","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Butera","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"Contessa","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Faraoni","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sangiovanni","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Negri","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Falchi","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bacis","sequence":"additional","affiliation":[{"name":"Bergamo Teratology Information Service, Papa Giovanni XXIII Hospital , 24100 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2021052709591271204_j_jpm-2020-0339_ref_001_w2aab3b7c38b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Bernucci, C, Brembilla, C, Veiceschi, P. Effects of the COVID-19 outbreak in northern Italy: perspectives from the Bergamo neurosurgery department. World Neurosurg 2020;137:456\u20138.e1. https:\/\/doi.org\/10.1016\/j.wneu.2020.03.179.","DOI":"10.1016\/j.wneu.2020.03.179"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_002_w2aab3b7c38b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Perin, A, Servadei, F, DiMeco, F. \u2018Hub and Spoke\u2019 Lombardy neurosurgery group. May we deliver neuro-oncology in difficult times (e.g. COVID-19)? J Neuro Oncol 2020;148:203\u20135. https:\/\/doi.org\/10.1007\/s11060-020-03496-7.","DOI":"10.1007\/s11060-020-03496-7"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_003_w2aab3b7c38b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Grein, J, Ohmagari, N, Shin, D, Diaz, D, Asperges, E, Castagna, A, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020;382:2327\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2007016.","DOI":"10.1056\/NEJMc2015312"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_004_w2aab3b7c38b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Zhang, W, Zhao, Y, Zhang, F, Wang, Q, Taisheng, L, Zhengyin, L, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 2020;214:108393. https:\/\/doi.org\/10.1016\/j.clim.2020.108393.","DOI":"10.1016\/j.clim.2020.108393"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_005_w2aab3b7c38b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Yao, X, Ye, F, Zhang, M, Cui, C, Huang, B, Niu, P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732\u20139. https:\/\/doi.org\/10.1093\/cid\/ciaa237.","DOI":"10.1093\/cid\/ciaa237"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_006_w2aab3b7c38b1b6b1ab2b1b6Aa","unstructured":"Ye, XT, Luo, YL, Xia, SC, Sun, QF, Ding, JG, Zhou, Y, et al. Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci 2020;24:3390\u20136. https:\/\/doi.org\/10.26355\/eurrev_202003_20706."},{"key":"2021052709591271204_j_jpm-2020-0339_ref_007_w2aab3b7c38b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Livingston, E, Bucher, K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 2020;323:1335. https:\/\/doi.org\/10.1001\/jama.2020.4344.","DOI":"10.1001\/jama.2020.4344"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_008_w2aab3b7c38b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Devaux, CA, Rolain, JM, Colson, P, Raoult, D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020:55:105938. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105938.","DOI":"10.1016\/j.ijantimicag.2020.105938"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_009_w2aab3b7c38b1b6b1ab2b1b9Aa","unstructured":"Kaplan, YC, Koren, G. Use of hydroxychloroquine during pregnancy and breastfeeding: an update for the recent coronavirus pandemic (COVID-19). Motherisk Int J 2020;1:9."},{"key":"2021052709591271204_j_jpm-2020-0339_ref_010_w2aab3b7c38b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Kaplan, YC, Ozsarfati, J, Nickel, C, Koren, G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;81:835\u201348. https:\/\/doi.org\/10.1111\/bcp.12872.","DOI":"10.1111\/bcp.12872"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_011_w2aab3b7c38b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Ullberg, S, Lindquist, NG, Sjostrand, SE. Accumulation of chorioretinotoxic drugs in the foetal eye. Nature 1970;227:1257\u20138. https:\/\/doi.org\/10.1038\/2271257a0.","DOI":"10.1038\/2271257a0"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_012_w2aab3b7c38b1b6b1ab2b1c12Aa","unstructured":"Paufique, L, Magnard, P. Retinal degeneration in two children following preventive antimalarial treatment of the mother during pregnancy. Bull Soc Ophtalmol Fr 1969;69:466\u20137."},{"key":"2021052709591271204_j_jpm-2020-0339_ref_013_w2aab3b7c38b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Sarkar, M, Woodland, C, Koren, G, Einarson, AR. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006;6:18. https:\/\/doi.org\/10.1186\/1471-2393-6-18.","DOI":"10.1186\/1471-2393-6-18"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_014_w2aab3b7c38b1b6b1ab2b1c14Aa","unstructured":"Rao, GN, Giles, HD. Reproductive and developmental toxicity of AIDS combination therapies in Swiss (CD-1N) mice. Toxicologist 2000;54:227."},{"key":"2021052709591271204_j_jpm-2020-0339_ref_015_w2aab3b7c38b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Andersen, JT, Petersen, M, Jimenez-Solem, E, Broedbaek, K, Andersen, NL, Torp-Pedersen, C, et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. PloS One 2013;8:e53327.https:\/\/doi.org\/10.1371\/journal.pone.0053327.","DOI":"10.1371\/journal.pone.0053327"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_016_w2aab3b7c38b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Bar-Oz, B, Diav-Citrin, O, Shechtman, S, Tellem, R, Arnon, J, Francetic, I, et al. Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study. Eur J Obstet Gynecol Reprod Biol 2008;141:31\u20134.https:\/\/doi.org\/10.1016\/j.ejogrb.2008.07.008.","DOI":"10.1016\/j.ejogrb.2008.07.008"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_017_w2aab3b7c38b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"B\u00e9rard, A, Sheehy, O, Zhao, JP, Nordeng, H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf 2015;24:1241\u20138.https:\/\/doi.org\/10.1002\/pds.3900.","DOI":"10.1002\/pds.3900"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_018_w2aab3b7c38b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Lin, KJ, Mitchell, AA, Yau, WP, Louik, C, Hern\u00e1ndez-D\u00edaz, S. Maternal exposure to amoxicillin and the risk of oral clefts. Epidemiology 2012;23:699\u2013705.https:\/\/doi.org\/10.1097\/EDE.0b013e318258cb05.","DOI":"10.1097\/EDE.0b013e318258cb05"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_019_w2aab3b7c38b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"M\u00f8lgaard-Nielsen, D, Hviid, A. Maternal use of antibiotics and the risk of orofacial clefts: a nationwide cohort study. Pharmacoepidemiol Drug Saf 2012;21:246\u201353.https:\/\/doi.org\/10.1002\/pds.2179.","DOI":"10.1002\/pds.2179"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_020_w2aab3b7c38b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Damkier, P, Br\u00f8nniche, LMS, Korch-Frandsen, JFB, Broe, A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol 2019;221:648.e1-648.e15.https:\/\/doi.org\/10.1016\/j.ajog.2019.06.050.","DOI":"10.1016\/j.ajog.2019.06.050"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_021_w2aab3b7c38b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Kenyon, SL, Taylor, DJ, Tarnow-Mordi, W. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE collaborative group. Lancet 2001;357:979\u201388.https:\/\/doi.org\/10.1016\/s0140-6736(00)04234-3.","DOI":"10.1016\/S0140-6736(00)04233-1"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_022_w2aab3b7c38b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Ehsanipoor, RM, Chung, JH, Clock, CA, McNulty, JA, Wing, DA. A retrospective review of ampicillin-sulbactam and amoxicillin + clavulanate vs cefazolin\/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: maternal and neonatal outcomes. Am J Obstet Gynecol 2008;198:e54\u20136. https:\/\/doi.org\/10.1016\/j.ajog.2007.12.022.","DOI":"10.1016\/j.ajog.2007.12.022"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_023_w2aab3b7c38b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Hoeltzenbein, M, Beck, E, Rajwanshi, R, Gotestam Skorpen, C, Berber, E, Schaefer, C, et al. Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 2016;46:238\u201345.https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.004.","DOI":"10.1016\/j.semarthrit.2016.05.004"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_024_w2aab3b7c38b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Weber-Schoendorfer, C, Schaefer, C. Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center. Reprod Toxicol 2016;60:29\u201332. Epub 2016 Jan 21. PubMed PMID: 26806369. https:\/\/doi.org\/10.1016\/j.reprotox.2016.01.002.","DOI":"10.1016\/j.reprotox.2016.01.002"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_025_w2aab3b7c38b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Nakajima, K, Watanabe, O, Mochizuki, M, Nakasone, A, Ishizuka, N, Murashima, A. et al. Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan. Mod Rheumatol 2016;26:667\u201371.https:\/\/doi.org\/10.3109\/14397595.2016.1147405.","DOI":"10.3109\/14397595.2016.1147405"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_026_w2aab3b7c38b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Kaneko, K, Sugitani, M, Goto, M, Murashima, A. Tocilizumab and pregnancy: four cases of pregnancy in young women with rheumatoid arthritis refractory to anti-TNF biologics with exposure to tocilizumab. Mod Rheumatol 2016;26:672\u20135. https:\/\/doi.org\/10.3109\/14397595.2016.1140256.","DOI":"10.3109\/14397595.2016.1140256"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_027_w2aab3b7c38b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Zhang, S, Li, L, Shen, A, Chen, Y, Qi, Z. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Invest 2020:1\u20138. https:\/\/doi.org\/10.1007\/s40261-020-00917-3.","DOI":"10.1007\/s40261-020-00917-3"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_028_w2aab3b7c38b1b6b1ab2b1c28Aa","unstructured":"The U.S. Food and Drug Administration. Information for ACTEMRA \u00ae (tocilizumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125276s114lbl.pdf. [Accessed 15 Feb 2020]."},{"key":"2021052709591271204_j_jpm-2020-0339_ref_029_w2aab3b7c38b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Papp, E, Mohammadi, H, Loutfy, MR, Yudin, MH, Murphy, KE, Walmsley, SL, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis 2015;211:10\u20138.","DOI":"10.1093\/infdis\/jiu393"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_030_w2aab3b7c38b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Roberts, SS, Martinez, M, Covington, DL, Rode, RA, Pasley, MV, Woodward, WC. Lopinavir\/Ritonavir in pregnancy. J Acquir Immune Defic Syndr 2009;51:456\u201361.","DOI":"10.1097\/QAI.0b013e3181a2813f"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_031_w2aab3b7c38b1b6b1ab2b1c31Aa","unstructured":"Kawamura, S, Russel, AW, Freeman, SJ, Siddal, RA. [Reproduction and developmental study of meropenem in rats]. Nippon Kagaku Ryoho Gakkai Zasshi 1992;40(Suppl 1):238\u201350."},{"key":"2021052709591271204_j_jpm-2020-0339_ref_032_w2aab3b7c38b1b6b1ab2b1c32Aa","unstructured":"Bennett, PN. Use of the monographs on drugs. In: Bennett, PN, editor Drugs and human lactation, 2nd ed. London, UK: Elsevier; 1996."},{"key":"2021052709591271204_j_jpm-2020-0339_ref_033_w2aab3b7c38b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Sperber, K, Hom, C, Chao, CP, Shapiro, D, Ash, J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009;7:9.","DOI":"10.1186\/1546-0096-7-9"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_034_w2aab3b7c38b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Oumar, AA, Bagayoko-Maiga, K, Bahachimi, A, Maiga, M, Cere, MC, Diarra, Z, et al. Efavirenz and lopinavir levels in HIV-infected women and their nursing infants, in Mali. J Pharmacol Exp Therapeut 2018;366:479\u201384.","DOI":"10.1124\/jpet.118.249938"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_035_w2aab3b7c38b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Palombi, L, Pirillo, MF, Andreotti, M, Liotta, G, Erba, F, Sagno, JB, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012;17:1511\u20139.","DOI":"10.3851\/IMP2315"},{"key":"2021052709591271204_j_jpm-2020-0339_ref_036_w2aab3b7c38b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Corbett, AH, Kayira, D, White, NR, Davis, NL, Courti, AP, Chasela, C, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study. Antivir Ther 2014;19:587\u201395.","DOI":"10.3851\/IMP2739"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jpme\/48\/9\/article-p1001.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2020-0339\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2020-0339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T10:11:44Z","timestamp":1622110304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2020-0339\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,8,10]]},"published-print":{"date-parts":[[2020,11,26]]}},"alternative-id":["10.1515\/jpm-2020-0339"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2020-0339","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}